Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt No Debt
AFFY's Cash to Debt is ranked higher than
78% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. AFFY: No Debt )
AFFY' s 10-Year Cash to Debt Range
Min: 6.71   Max: 13531.29
Current: No Debt

6.71
13531.29
Equity to Asset 0.96
AFFY's Equity to Asset is ranked higher than
98% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. AFFY: 0.96 )
AFFY' s 10-Year Equity to Asset Range
Min: -3.14   Max: 0.96
Current: 0.96

-3.14
0.96
F-Score: 6
Z-Score: -117.89
M-Score: -9.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1099.05
AFFY's Operating margin (%) is ranked higher than
55% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. AFFY: -1099.05 )
AFFY' s 10-Year Operating margin (%) Range
Min: -45958.11   Max: -12.84
Current: -1099.05

-45958.11
-12.84
Net-margin (%) -1053.62
AFFY's Net-margin (%) is ranked higher than
55% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. AFFY: -1053.62 )
AFFY' s 10-Year Net-margin (%) Range
Min: -44021.62   Max: -12.51
Current: -1053.62

-44021.62
-12.51
ROA (%) -193.79
AFFY's ROA (%) is ranked lower than
51% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. AFFY: -193.79 )
AFFY' s 10-Year ROA (%) Range
Min: -193.79   Max: -10.71
Current: -193.79

-193.79
-10.71
Revenue Growth (%) -79.40
AFFY's Revenue Growth (%) is ranked higher than
55% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. AFFY: -79.40 )
AFFY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 187
Current: -79.4

0
187
EBITDA Growth (%) -7.50
AFFY's EBITDA Growth (%) is ranked higher than
76% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. AFFY: -7.50 )
AFFY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 25
Current: -7.5

0
25
EPS Growth (%) -11.90
AFFY's EPS Growth (%) is ranked higher than
75% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. AFFY: -11.90 )
AFFY' s 10-Year EPS Growth (%) Range
Min: -65.5   Max: 17.4
Current: -11.9

-65.5
17.4
» AFFY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AFFY Guru Trades in

AFFY Guru Trades in

Q1 2013

AFFY Guru Trades in Q1 2013

Jim Simons 1,027,867 sh (New)
Paul Tudor Jones 305,400 sh (New)
Steven Cohen Sold Out
» More
Q2 2013

AFFY Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-03-31 Sold Out 0.06%$6.53 - $14.31 $ 0.22-98%0
George Soros 2011-12-31 Add 800.9%0.05%$4.24 - $7.8 $ 0.22-96%200000
George Soros 2011-09-30 Reduce -83.4%0.01%$4.04 - $7.78 $ 0.22-96%22200
George Soros 2011-06-30 New Buy0.01%$5.85 - $7.16 $ 0.22-97%133717
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 3.50
AFFY's P/E(ttm) is ranked higher than
99% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: 3.50 )
AFFY' s 10-Year P/E(ttm) Range
Min: 0   Max: 6.4
Current: 3.5

0
6.4
P/B 1.57
AFFY's P/B is ranked higher than
90% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. AFFY: 1.57 )
AFFY' s 10-Year P/B Range
Min: 0.89   Max: 172
Current: 1.57

0.89
172
EV-to-EBIT -0.82
AFFY's EV-to-EBIT is ranked higher than
78% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: -0.82 )
AFFY' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.82

Current Ratio 20.81
AFFY's Current Ratio is ranked higher than
96% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. AFFY: 20.81 )
AFFY' s 10-Year Current Ratio Range
Min: 0.62   Max: 21.42
Current: 20.81

0.62
21.42
Quick Ratio 20.81
AFFY's Quick Ratio is ranked higher than
96% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. AFFY: 20.81 )
AFFY' s 10-Year Quick Ratio Range
Min: 0.62   Max: 21.42
Current: 20.81

0.62
21.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.76
AFFY's Price/Net Cash is ranked higher than
95% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. AFFY: 2.76 )
AFFY' s 10-Year Price/Net Cash Range
Min: 1.17   Max: 60.08
Current: 2.76

1.17
60.08
Price/Net Current Asset Value 2.76
AFFY's Price/Net Current Asset Value is ranked higher than
95% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. AFFY: 2.76 )
AFFY' s 10-Year Price/Net Current Asset Value Range
Min: 1.08   Max: 66.29
Current: 2.76

1.08
66.29
Price/Tangible Book 1.56
AFFY's Price/Tangible Book is ranked higher than
93% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. AFFY: 1.56 )
AFFY' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 120
Current: 1.56

0.76
120
Price/Graham Number 0.47
AFFY's Price/Graham Number is ranked higher than
99% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: 0.47 )
AFFY' s 10-Year Price/Graham Number Range
Min: 0.23   Max: 0.23
Current: 0.47

Earnings Yield (Greenblatt) 236.80
AFFY's Earnings Yield (Greenblatt) is ranked higher than
89% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AFFY: 236.80 )
AFFY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 21110.7
Current: 236.8

0
21110.7
Forward Rate of Return (Yacktman) -1112.88
AFFY's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. AFFY: -1112.88 )
AFFY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -1112.88

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:A5Y.Germany
Affymax, Inc. incorporated in Delaware in July 2001. It is a biopharmaceutical company discovering, developing and delivering innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. Its clinical trials include: Phase 3b Conversion Study (DIAMOND trial) and Phase 2 Study in Dialysis and Non-dialysis Patients with PRCA. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for AFFY

Headlines

Articles On GuruFocus.com
Dead Biotech Plays Surge To Life May 07 2013 
comment on AFFY Mar 15 2013 
comment on AFFY Mar 02 2013 
Weekly CFO Sells Highlight: PII, ASNA, FIO, VVUS, AFFY Jul 23 2012 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares May 19 2010 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares May 13 2010 
AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares Feb 26 2010 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares Sep 30 2009 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares Sep 02 2009 
AFFYMAX, INC. Reports Operating Results (10-Q) Aug 05 2009 

More From Other Websites
AFFYMAX INC Financials Aug 09 2014
AFFYMAX INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
Affymax Reports Second Quarter 2014 Financial Results Jul 31 2014
AFFYMAX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 18 2014
AFFYMAX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2014
Affymax board announces decision to dissolve company Jun 24 2014
Affymax Board Announces Decision to Dissolve the Company Jun 24 2014
AFFYMAX INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements... Jun 13 2014
Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and... Jun 13 2014
Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and... Jun 13 2014
AFFYMAX INC Files SEC form 8-K, Other Events May 14 2014
AFFYMAX INC Files SEC form 10-Q, Quarterly Report May 06 2014
AFFYMAX INC Files SEC form 10-K, Annual Report Mar 31 2014
AFFYMAX INC Files SEC form 10-Q, Quarterly Report Nov 05 2013
New Data Show Omontys At Least 4x Worse Than Reported: Now 22 Suspected Deaths Oct 14 2013
Just Like Omontys.com, Affymax Is Likely To Disappear Sep 10 2013
AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Aug 20 2013
AFFYMAX INC Files SEC form 8-K, Other Events Aug 16 2013
AFFYMAX INC Files SEC form 10-Q, Quarterly Report Aug 05 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK